Zevra beefs up rare disease portfolio via $91M acquisition of Acer Therapeutics
Zevra Therapeutics is set to buy Acer Therapeutics in a deal worth up to $91 million, which finds the Florida-headquartered biotech with an additional two assets.
As a part of the deal, Zevra will absorb Acer’s urea cycle disorder treatment Olpruva (sodium phenylbutyrate), which secured an FDA approval in December last year, as well as beta-blocker celiprolol, which is in a Phase III vascular Ehlers-Danlos syndrome trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.